Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medpharm Holdings LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, reflecting a focused prosecution strategy. Because the total number of pending office actions is 1, the entire active portfolio is under the review of this single examiner. This indicates a singular focus within the biotechnology sector, likely targeting a specific pharmaceutical development.
Nizal S Chandrakumar is the busiest examiner for the company, managing 1 busiest examiner pending action. The portfolio is limited to 1 distinct art unit. This concentration in 1 distinct art unit suggests that the subject matter is highly specialized within the biotechnology field. For practitioners, the alignment of the 1 pending office action with a single examiner and art unit means that the prosecution strategy is entirely dependent on the specific requirements of Nizal S Chandrakumar. This singular focus allows for a deep and consistent technical dialogue during the examination process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18195517 | SELF-EMULSIFYING ANHYDROUS INTRADERMAL DEPOT GEL | CHANDRAKUMAR, NIZAL S | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18195517 | SELF-EMULSIFYING ANHYDROUS INTRADERMAL DEPOT GEL | CHANDRAKUMAR, NIZAL S | 33d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18195517 | SELF-EMULSIFYING ANHYDROUS INTRADERMAL DEPOT GEL | CHANDRAKUMAR, NIZAL S | 1625 | §101Other | Final Rejection | 33d | Pending | May 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial